Zhihua Li

机构：Sun Yat-sen University, Princess Margaret Cancer Centre, Chengdu Sport University, Sun Yat-sen Memorial Hospital, Third Hospital of Nanchang, Second Hospital of Nanchang, Heron Therapeutics (United States), Jiangsu Province Hospital, Nanjing Medical University · ORCID：0000-0003-2003-5457

发表论文 81 篇 · 总被引 2912 次 · h-index 28

代表论文

• SUMOylation-triggered ALIX activation modulates extracellular vesicles circTLCD4-RWDD3 to promote lymphatic metastasis of non-small cell lung cancer (2023 · Signal Transduction and Targeted Therapy · 被引 52)
• Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors. (2024 · Journal of Clinical Oncology · 被引 36)
• Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 29)
• A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation. (2024 · Journal of Clinical Oncology · 被引 20)
• Tai chi improves balance performance in healthy older adults: a systematic review and meta-analysis (2024 · Frontiers in Public Health · 被引 19)
• The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China (2023 · Journal of Pancreatology · 被引 14)